Artificial Intelligence for Hospital Cancer Immunotherapy: Market Shares, Strategies, and Forecasts, Worldwide, 2017 to 2023
WinterGreen Research announces that it has published a new study Artificial Intelligence for Hospital Cancer Immunotherapy: Market Shares, Strategy, and Forecasts, Worldwide, 2017 to 2023. The 2017 study has 124 pages, 50 tables and figures. Worldwide markets are poised to achieve continuing growth as the artificial intelligence software increases diagnostic excellence, saving lives and lowering care delivery costs.
Hospital Artificial Intelligence for Immunotherapy drives sales of analytics systems.
Automated cancer immunotherapies from IBM Watson are implemented with artificial intelligence that looks at patient samples to detect the genetic characteristics of the cancer and isolate the immune particularities of the patient. Systems are able to take a multi-disciplinary integrated approach to looking at imaging and scans. The analysis of patient records, looking for effectiveness of particular treatments is more work than a human can do, the quantity of data is too high, so the artificial intelligence is being used to do that.
Personalized medicine is driving this market opportunity.
Systems are making a significant difference in saving lives.
Memorial Sloan Kettering physician-scientists are among leaders in the field developing groundbreaking immune therapies that are helping to treat several forms of advanced cancer that were previously untreatable. These scientists have played a lead role in developing and testing the immunotherapy drugs known as checkpoint inhibitors that “release the brakes” on the immune system.
Hospital care management can leverage artificial intelligence. Artificial intelligence is useful for providing highly tailored insights about individual patients for the purpose of personalizing immunotherapy care delivery. Artificial intelligence is useful for helping providers effectively address healthcare delivery because it details genetic specificity regarding individual patients.